In an email, a Gilead spokesperson explained that the reductions are to “further align our resources as we prepare for the upcoming launch of twice-yearly lenacapavir for HIV and other near-term launches.”
https://www.fiercepharma.com/pharma/bay-area-gilead-cuts-149-while-roche-eliminates-108-jobs